Breakout Ventures closes $114M fund, plans 20 investmentsnews2026-03-10T11:00:55+00:00March 10th, 2026|Endpoints News|
BioNTech co-founders to exit company and start a new onenews2026-03-10T10:30:30+00:00March 10th, 2026|Endpoints News|
Ipsen pulls cancer drug Tazverik from market over safety risksnews2026-03-09T18:16:40+00:00March 9th, 2026|Endpoints News|
What Prasad’s exit means for the FDA moving forwardnews2026-03-09T17:51:46+00:00March 9th, 2026|Endpoints News|
Universal Health Services buys Talkspace for $835Mnews2026-03-09T15:37:23+00:00March 9th, 2026|Endpoints News|
AbbVie, Gubra post obesity data; Regeneron obesity drug succeeds in Chinanews2026-03-09T15:17:36+00:00March 9th, 2026|Endpoints News|
Xenon gets Phase 3 win with epilepsy drug, setting up FDA approval filingnews2026-03-09T15:04:48+00:00March 9th, 2026|Endpoints News|
Hims agrees to limit compounding, ending feud with Novo Nordisknews2026-03-09T14:44:20+00:00March 9th, 2026|Endpoints News|
Bristol Myers says second CELMoD succeeds in Phase 3news2026-03-09T14:33:32+00:00March 9th, 2026|Endpoints News|
Incyte receives CRL over issues at Novo’s Indiana factorynews2026-03-09T13:21:57+00:00March 9th, 2026|Endpoints News|
